Publications

Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021. Lead author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) Collected in Hospitals from Europe, Asia, and Latin America (2019–2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019–2020). Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.

Frequency and Antimicrobial Susceptibility of Gram-negative Bacteria Isolated from Patients with Bloodstream Infections in United States (US) Medical Centers (2020–2021). Lead author: Helio Sader, IDWeek 2022, October 19-23, Washington DC.

Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex Clinical Isolates Causing Infection in United States Hospitals (2020–2021). IDWeek 2022. October 19-21, 2022. Washington DC.

Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations Against AmpC-Producing Species Collected in United States Hospitals. Lead Author: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Dual VIM-Producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program. Lead Author: Gauri Deshpande; Presented by: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa Isolates from United States Medical Centers (2020-2021). Lead Author: HS Sader at IDWeek 2022, October 19-23, Washington DC.

In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020–2021) Stratified by Infection Type. Lead Author: Mike Huband, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations. Lead Author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the
United States. Lead Author: Rodrigo Mendes. IDWeek 2022. October 19-21, 2022. Washington DC.

Increase in the Occurrence of Carbapenem-Resistant Enterobacterales in United States Hospitals from 2019 to 2021 and Activity of Novel β-Lactam/
β-Lactamase Inhibitor Combinations Against These Isolates. Lead author: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016–2021). Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Activity of Oritavancin and Comparator Agents Against Coagulase-Negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019). Lead author: Cecilia G Carvalhaes, IDWeek 2022, October 19-23, Washington DC.

Activity of Meropenem-Vaborbactam and Comparators AgainstEnterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic
Fibrosis Patients. Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Prevalence, Phenotypic and Genotypic Characteristics, and Clinical Presentations of Staphylococcus argenteus Causing Bloodstream Infections in United States Hospitals. Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftazidime-Avibactam and Other New β-Lactamase Inhibitor Combinations Tested against Bacterial Isolates from Pediatric
Patients from US Medical Centers (2020–2021). Lead author: Helio Sader. IDWeek 2022. October 19-21. Washington DC.

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021). Lead Author: Michael Huband, IDWeek 2022, October 19-21, Washington DC.

Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017–2021). Lead author: Cecilia Carvalhaes, IDWeek 2022, October 18-21, Washington DC.

Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents by Castanheira M, Deshpande LM, Mendes RE, Doyle TB, Sader HS in JAC-Antimicrob. Resist. 2022; 4(5): dlac098.

Activity of Meropenem/Vaborbactam and Comparators against non-carbapenemase producing carbapenem-resistant Enterobacterales isolates from Europe by Shortridge D, Deshpande L, Streit J, and Castanheira M in JAC – Antimicrob. Resist. 2022; 4 (5): dlac097.

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019) by Pfaller MA, Mendes RE, Streit JM, Carvalhaes, CG in Diagnostic Microbiology and Infectious Disease 2022; 104: 115804.

Antimicrobial Activity of Ceftaroline and Comparator Agents Against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020) by Sader HS, Castanheira M, Carvalhaes CG, Arends SJR, Mendes RE in Microbial Drug Resistance 2022; 28 (9): 935-940.

Activity of Gepotidacin against Escherichia coli isolates from urinary tract infections collected between 2019-2021 from Germany and other European Countries. Lead author: SJ Ryan Arends, presented by C Ress at German Society for Urology 2022, September 21-24, Hamburg, Germany

Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019) by Carvalhaes CCG, Sader HS, Rhomberg PR, Castanheira M, DeVries S, Mendes RE in Pediatr. Infect. Dis. J. 41(9):2022, 731-735.

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018 by Shortridge D, Streit J, Pfaller M, Tulloch M, Chen WT, Castanheira M in J. Glob. Antimicrob. Resist. 31 (2022): 98-103.

Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme by Carvalhaes CG, Sader HS, Streit JM, Mendes RE in JAC-Antimicrob. Resist. 4(5): 2022, dlac088

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii by Michaeli J, Mandel S, Maximov S, Zazoun J, Savoia P, Kothari N, Valmont T, Ferrari L, Duncan LR, Hawser S, Cohen-Kutner M, Bachnoff N in antibiotics 11 (2022): 201.

Rezafungin in vitro activity against Candida spp. causing invasive infections in hematology/oncology and transplant units worldwide (2014-2021). Lead Author: Cecilia Carvalhaes. Presented at International Immunocompromised Host Society (ICHS 2022), Basel, Switzerland, 8-11 September 2022.

Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications by Rogers TR, Verweij PE, Castanheira M, Dannaoui E, White PL, Arendrup, MC on behalf of the Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) in J. Antimicrob. Chemother. 10:2022, dkac61.

Azole resistance in Candida glabrata clinical isolates from global surveillance is associated with efflux overexpression by Castanheira M, Deshpande L, Davis A, Carvalhaes C, Pfaller M in J. Glob. Antimicrob. Resist. 29: 2022, 317-377.

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes by Mendes RE, Rhomberg, PR, Watters AA, Castanheira M in J. Antimicrob. Chemother. 77(3): 2022, 689-694.

Ceftibuten-avibactam (fixed 4 μg/mL), ceftibuten, and ceftazidime-avibactam (fixed 4 μg/mL) broth microdilution quality control ranges using a CLSI M23 (2018) multi-laboratory study design. Lead Author: MD Huband presented at ASM Microbe 2022, June 9-13, 2022, Washington DC

Frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of Gram-negative and Gram-positive organisms via single-step mutational analysis. Lead author: SJ Ryan Arends presented at ASM Microbe 2022, June 9-13, Washington DC

Comparison of the VITEK2 Advanced Expert System phenotyping and genetic characterization of β-Lactamase genes for Enterobacterales isolates from North and Latin America. Lead author: CG Carvalhaes, presented at ASM Microbe 2022, June 9-13, Washington DC, USA

Poster #2427

The NCI and NIAID collaborative screen of the NPNPD Natural Product Fraction Library identified selective antimicrobial activity from natural source. Lead author: Leonard Duncan presented at ASM Microbe 2022, June 9-13, Washington DC

MIC predictions for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model presented by M Castanheira at ASM Microbe 2022, June 9-13, Washington DC

High-throughout screening of the Natural Product Discovery Fraction Library from the National Cancer Institute identified fractions with selective antimicrobial activity presented by SJ Ryan Arends at ASM Microbe 2022, June 9-13, Washington DC.

Evaluation of bactericidal activity, post-antibiotic, and sub-inhibitory effect of gepotidacin against various Gram-negative and Gram-positive isolates. Lead Author: SJ Ryan Arends presented at ASM Microbe 2022, June 9-13, Washington DC

Prediction of MIC values for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model. Lead author: Cory Hubler, presented at ASM Microbe 2022, June 9-13, Washington DC

In vitro activity of manogepix against 1,435 fungal isolates collected worldwide during the SENTRY surveillance program (2020). Lead Author: MD Huband presented at ASM Microbe 2022, June 9-13, 2022, Washington DC

Detection of the carbapenem-hydrolyzing CTX-M-15 variant, CTX-M-33, among carbapenem-nonsusceptible Klebsiella pneumoniae isolates from Poland. Lead author Mariana Castanheira presented at ASM Microbe 2022, June 9-13, Washington DC

Comparison of MIC results for gepotidacin by agar dilution and broth microdilution methods for various Gram-positive and Gram-negative species. Lead author SJ Ryan Arends. Presented at ASM Microbe 2022, June 9-13, Washington DC

Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections by Pfaller MA, Carvalhaes CG, DeVries S, Rhomberg PR, Castanheira M in Med. Mycol. J. 2022; 6 (60): myac028.

In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072) against clinical isolates with molecularly characterized tetracycline resistance mechanisms by Pfaller MA, Li L, Liu Q, Zhang J, Huband MD, Lindley JM, Mendes RE in J. Glob. Antimicrob. Resist. 3(4): 2021, dlab177.

In vitro potency and spectrum of the novel polymycin MRX-8 tested against clinical isolates of Gram-negative bacteria by Duncan LR, Wang W, Sader HS in Antimicrob. Agents Chemother. 2022; 66 (5): 10.1128.